The vulvodynia treatment market is currently worth US$ 5.6 billion, and it is anticipated to reach US$ 8 billion by 2028, growing at an impressive CAGR of 6.3% from 2022 to 2028.
In order to cater to the need of the growing number of patients, companies are looking out for treatments and drugs that can subside the pain related to vulvodynia. Towards this, they are investing in research and development and mergers and acquisitions. For instance, in January 2016, Merck & Co. Inc., acquired IOmet Pharma Ltd., a privately held U.K.-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. The other leading companies operating in the market are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc, among others.
Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4985
According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.1% over the forecast period of 2018 and 2028. The market was worth US$ 4,261.2 Mn in 2017 and is expected to rise to a valuation of US$ 8,091.6 Mn by the end of 2028.
Growing Adoption to Augur Well for Global Market Revenue Growth
The swelling number of patients suffering from vulvodynia and harsh nature of chronic vulvar pain have led to the adoption of early diagnosis and treatment. The adequate results of medical treatments such as drugs, injections and creams have increased the preference for medication to treat vulvodynia. Furthermore, increasing adoption of medicinal treatments of vulvodynia has resulted in an increase in the sales of hormones, local anesthetics, and antidepressants. Additionally, promising compensation policies in most of the developed countries are also expected to act as a value driver to the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of the vulvodynia disease among women across the globe is a core factor that is pushing the growth of the vulvodynia treatment market. Vulvodynia is a very common disease in the United States and across the globe. Nevertheless, the ailment remains underdiagnosed or in some cases also incompetently treated.
Key Takeways:
- Growing Prevalence: Vulvodynia, a chronic pain condition affecting the vulva, is becoming increasingly prevalent, driving demand for treatment options.
- Lack of Standardized Treatment: Currently, there is no universally accepted or standardized treatment for vulvodynia, leading to a variety of therapeutic approaches, both medical and non-medical.
- Evolving Research: Ongoing research and clinical trials are exploring new treatment modalities, including topical creams, medications, physical therapy, and psychological interventions.
- Patient-Centric Care: Personalized treatment plans are essential, as vulvodynia can vary widely in terms of symptoms and severity among patients, highlighting the importance of individualized care.
- Rising Awareness: Increased awareness about vulvodynia is helping patients seek medical assistance earlier, which in turn is contributing to the growth of the vulvodynia treatment market.
- Market Growth: The vulvodynia treatment market is expected to continue its growth trajectory as healthcare providers, pharmaceutical companies, and researchers work together to develop more effective and accessible treatment options for this challenging condition.
Key Companies Profiled:
- Eli Lilly and Company
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Allergan plc
Key Segments:
Vulvodynia Treatment Market by Drug Class:
- Local Anesthetics
- Anticonvulsant
- Tricyclic Antidepressants
- Hormones
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- Nerve Blocks
- Others
Vulvodynia Treatment Market by Mode of Application:
- Oral Vulvodynia Treatment
- Topical Vulvodynia Treatment
- Injection Vulvodynia Treatment
Vulvodynia Treatment Market by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Online Pharmacies
Vulvodynia Treatment Market by Region:
- North America Vulvodynia Treatment Market
- Latin America Vulvodynia Treatment Market
- Europe Vulvodynia Treatment Market
- East Asia Vulvodynia Treatment Market
- South Asia & Pacific Vulvodynia Treatment Market
- Middle East & Africa (MEA) Vulvodynia Treatment Market
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-4985
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube